Drug-coated balloons show comparable major outcomes
Drug-coated balloons could provide an alternative to permanent coronary stents for some people undergoing angioplasty, according to an analysis led by researchers at the University of East Anglia. The study combined data from 10 randomized clinical trials involving 7,832 patients with coronary artery disease.
Coronary artery disease narrows blood vessels that supply the heart, reducing blood flow and raising the risk of serious cardiac events. A common treatment is angioplasty, in which clinicians open a narrowed artery. Drug-releasing stents, small mesh tubes left inside the artery, are widely used during that procedure.
The analysis compared those stents with drug-coated balloons. The balloon is inflated at the narrowed portion of an artery and releases medicine into the artery wall. It is then removed, leaving no metal implant behind.
Researchers reported no meaningful difference between the two approaches for the study’s most serious outcomes. Patients treated with drug-coated balloons were no more likely to die from cardiovascular causes than patients receiving stents, and heart-attack rates were described as virtually identical.
Evidence from randomized trials
The pooled evidence drew on trials that randomly assigned participants to one of the two treatments. The finding remained unchanged when the researchers excluded studies focused only on small coronary arteries, an area in which drug-coated balloons already have an established evidence base.
That consistency matters because it suggests the comparison was not driven solely by results in smaller vessels. The researchers examined coronary artery disease more broadly, while recognizing that treatment decisions still depend on a patient’s anatomy and clinical circumstances.
Lead researcher Natasha Corballis of UEA’s Norwich Medical School said the work found no meaningful difference between the treatments on the major outcomes assessed. The findings were published in eClinicalMedicine.
A trade-off: more repeat procedures
The results do not mean the two approaches are interchangeable in every respect. The study also found that some people treated with drug-coated balloons may be more likely to need another procedure later. The article specifically flags repeat procedures as a consideration in larger arteries.
That trade-off is central to interpreting the findings. Avoiding a permanent implant may be appealing in appropriate cases, but clinicians and patients must weigh that potential advantage against the possibility that the treated artery could require another intervention.
Drug-coated balloons and drug-releasing stents are designed to address the same problem: limiting the chance that a treated vessel narrows again. They do so differently. A stent provides a physical scaffold that stays in the artery, while a drug-coated balloon delivers medicine during inflation and is removed after treatment.
What the analysis changes
The analysis adds evidence that a “leave nothing behind” strategy can achieve similar results to conventional stenting for cardiovascular death and heart attack in the studied population. It does not establish that balloons should replace stents for all angioplasty patients.
Instead, it broadens the treatment discussion. For patients whose circumstances make avoiding a permanent implant desirable, drug-coated balloons may be a clinically credible option, provided the risk of future repeat treatment is considered.
Further work will be important to clarify which patients and artery types are best suited to each approach. For now, the pooled trial data indicate that the choice need not be framed only around the presence or absence of a stent: major cardiovascular outcomes were comparable, while durability and the need for later procedures remain part of the decision.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
